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Abstract

Allergies are a major public health problem affecting over 300 million people worldwide
(Asamoah et. al). An allergic response can occur when a harmless substance, such as tree pollen,
is inhaled into the body and mistakenly identified as a harmful substance. Antibodies then bind
to the allergen causing a release of chemicals that leads to symptoms such as nasal congestion,
runny nose, itchy eyes or skin reactions. For some people, this reaction can also affect the lungs
and airways leading to asthma symptoms.

This review analyzes articles from PubMed, Cochran, Clinical Key and references found
from UpToDate articles to assess the effect that allergens have on the upper respiratory system
on a pathophysiological basis and to evaluate how immunotherapy can be used to decrease the
hypersensitive reaction that occurs in people with allergy-induced asthma.
Researchers have found that immunotherapy can decrease the immune system’s
hypersensitivity and reduce the release of inflammatory cells. As a result, people with allergyinduced asthma were able to increase their immune system and decrease their use of medication
and emergency room visits. Through these studies, the effectiveness of both subcutaneous and
sublingual immunotherapies were compared in an attempt to provide a better understanding of
both methods. These studies faced several challenges, including: the costs of the studies;
difficulty controlling outside influences such as pollen levels; and the commitment of each
patient to see the trial through to completion.
Results from these studies concluded that immunotherapy can reduce the sensitivity to
those allergens that contribute to asthma symptoms in people whose medication therapy cannot
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keep their symptoms under control. Although the results of these studies are encouraging, larger
studies with greater sample sizes are warranted to reaffirm the knowledge gained in these studies
and the positive effects of immunotherapy on people suffering from allergies and allergic
asthma.
Keywords: Immunotherapy; Allergic Asthma; Hypersensitivity; Allergies; Asthma; Physiology;
SCIT; SLIT.

Introduction
Seasonal allergies are a major problem around the world. Respiratory allergies were the
most common type of allergy among children ages 0 to 17 between 1997-2011 with 17% of this
population presenting with symptoms (Jackson, Howie, & Akinbami, 2013). Chronic nasal
congestion can lead to respiratory problems, and many people treat allergies on a routine basis
with over-the-counter medications. Antihistamines and leukotriene antagonists are common
medications that can decrease the symptoms of select allergies; however, the use of
immunotherapy is the only approach that has been shown to decrease a person’s sensitivity to
allergies at a cellular level.
People who suffer from allergies are at a higher risk of having asthma which can cause
impaired ventilation. Children who are polysensitized early in life face a greater chance of being
diagnosed with asthma and have a greater risk of hospitalization for wheezing or asthma
(Yukselen & Kendirli, 2014). Immunotherapy is a process that requires a long-term commitment
but has the potential to improve the overall health of the patient. A key concern when dealing
with patients exhibiting chronic allergies is the progression into allergic asthma, but with
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continued education and the use of immunotherapy it is possible to desensitize those patients
with allergen-specific immunoglobulins.
The purpose of this scholarly project is to determine if patients exhibiting uncontrolled
allergic asthma can benefit from immunotherapy to decrease their sensitivity to specific allergens
and lessen their asthmatic symptoms, thus reducing their need for the use of medication and to
evaluate the difference in beneficial uses between subcutaneous immunotherapy (SCIT) and
sublingual immunotherapy (SLIT). This scholarly project will also address two different
delivery methods of immunotherapy and compare the effectiveness of both.

Statement of the Problem
Asthma and allergic rhinitis are two of the most common chronic medical conditions
across the world affecting around 300 million people (Yukselen & Kendirli, 2014). Allergic
rhinitis alone has an estimated cost of more than $2 billion dollars annually within the United
States, and roughly 40% of the patients with allergic rhinitis also report coexisting asthma
(Mener & Lin, 2016). There is a need for more quality research and evidence-based guidelines
to further educate medical providers on the treatment options for patients when it is determined
that medications are not effectively managing their allergy and asthma conditions and to
demonstrate how immunotherapy can affect these conditions.
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Research Questions
1)

Can immunotherapy decrease the exacerbation of asthma symptoms in patients with
allergic asthma as compared to treatment with inhaled corticosteroids?

2)

In patients with allergic asthma, is subcutaneous immunotherapy (SCIT) or sublingual
immunotherapy (SLIT) a more effective treatment plan in managing to allergic asthma?

Methodology

Research for this scholarly project was obtained by searching each of the PubMed, and
Cochrane databases for articles related to immunotherapy and asthma. From this research,
articles were selected that included randomized controlled studies, systematic reviews, and
observational studies. Several keywords were used when researching articles in these databases
including; “allergic asthma”, “hypersensitivity”, “allergies”, “asthma”, “allergy physiology”,
“immunotherapy”, “allergy shots”, “SCIT”, and “SLIT”. The sources for the randomized
double-blind studies came solely from the PubMed database as the other databases had little to
no information regarding double-blind studies. Although there were no age or time restrictions
performed during the searches, most articles found focused their research on children varying in
ages from 4 to 18 years. Several articles were researched and reviewed to evaluate the
physiological effects of allergic asthma to come to a full understanding of its effect on the body.
The remaining articles assessed the effect of immunotherapy on medication usage and hospital
visits.
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The number of studies on the effects of immunotherapy on asthma were small, and a
majority of those studies focused on household dust mites (HDM) specifically.

Review of Literature
Having allergies can mean something different for each person. There are some people
who only have seasonal allergies, and they make do with over-the-counter medications as
needed. Others have year-round symptoms but manage them with over-the-counter drugs such
as loratadine or fluticasone propionate nasal spray and feel as if this is sufficient to allow them to
keep going throughout the day. However, people who suffer everyday congestion and headaches
without relief will go to great lengths to improve their quality of life. Most have tried multiple
medications and still have problems breathing and functioning to their optimal potential. With a
projected surge in the world’s urban population it is estimated that by 2025 an additional 100
million people may develop asthma, and therefore asthma is set to become one of the world’s
most prevalent chronic diseases (Asamoah et al., 2017). Traditionally, immunotherapy has been
the last resort for a lot of people, but for some it can be a life-changing experience.

Pathophysiology:
An allergic response occurs when a harmless allergen is inhaled into the body and the
immune system’s antibodies mistake that allergen as a harmful substance with a prevalence of
allergic rhinitis occurring in 5% to 22% of people with allergies (Khan, 2014). The body binds
to the allergen to protect itself causing a release of chemicals leading to one’s symptoms of nasal
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congestion, runny nose, itchy eyes, and skin reactions. This release of chemicals can even affect
the lungs and possibly lead to asthma.
Asthma is a common disease that affects 5% to 16% of people worldwide. Although
19% to 38% of patients with allergic rhinitis have concomitant asthma, a much higher frequency
of patients with asthma have concomitant allergic rhinitis (Khan, 2014). Allergy sensitization
occurs within the body when an antigen-presenting cell, like a macrophage, is present in the
mucosal surface of the body and it detects an allergen that has been breathed in through the nose
or mouth. At this time the antigen will be taken up by the antigen-presenting cell and displayed
on its surface. The antigen-presenting cell will then migrate toward the T-lymphocyte and
present the allergen to it which, in turn, stimulates B-cell to produce specific antibodies to the
allergen (Singh, Mehrotra, & Agarwal 1999). The antibodies that are produced are known as the
IgE immunoglobulins, and they will attach themselves to high-affinity receptors on the surface of
the mast cells. At this point the patient’s body has become more sensitive to the specific allergen
so when the patient’s body encounters the same allergen again IgE will stimulate the mast cell to
activate resulting in degranulation and leading to an inflammatory response. It is thought that the
most crucial function of IgE in allergic diseases is its ability to sensitize mast cells to release
biologically active mediators in an antigen-specific manner (Galli & Mindy 2012). This will
include mostly histamine and other mediators such as leukotrienes and prostaglandins.
The mast cells activated by IgE and specific antigens produce mediators that drive early
phase reactions and contribute to late phase reactions, but these mast cells also secrete
diverse cytokines, chemokines and growth factors that have the potential to influence
airway remodeling (Galli & Mindy 2012).

IMMUNOTHERAPY AND ASTHMA

10

The leukotrienes increase microvascular permeability that results in edema and narrowing of the
airways and stimulate the secretion of mucus in the lower respiratory tract. This damage
contributes to the chronic changes seen in patients, such as airway remodeling and associated
airway hyperresponsiveness.
Allergen-specific immunotherapy (SIT) can modify the course of allergic disease by
preventing exacerbation, reducing the risk of new allergic sensitizations, and deterring
the development of clinical asthma in children treated for allergic rhinitis. Furthermore,
one of the main goals of SIT is to achieve sustained clinical effects in post-treatment
follow-up over a recommended period of three to four years (Karakoc-Aydiner et al.,
2015).
Allergen Specific Immunotherapy (ASI) is administered by giving small predetermined
doses of allergens to patients over a period (usually several years) and tapered to promote
immune tolerance, while bettering allergic symptoms (Akdis, 2017). SIT is the only treatment
that may change the natural course of allergy sensitivities from transforming into allergic asthma
and reduce the risk of acute respiratory exacerbations (Akdis, 2017). Traditional medication
with inhalant corticosteroids may help alleviate the symptoms associated with allergic asthma,
but only ASI has the potential to change the natural course of allergic asthma by reducing the
risk of respiratory exacerbations and symptoms.
While the mechanism of action of SCIT is not fully understood, it is based on the
principle that repeated allergen exposures in allergic individuals results in immune tolerance by
reducing the sensitivity to the allergen (James & Till, 2016). An initial early step in SCIT may
be the H2-dependent suppression of a high affinity IgE-receptor that is expressed on the surface
of the mast cells.
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Examination of the T cell response demonstrated that both Th2 (IL-4, IL-5 and IL-13)
and Th1 (IFN-γ) cytokine production was decreased while IL-10 levels were increased.
These IL-10 producing T cells were able to suppress allergen-specific T cell proliferation
and activation and are now recognized as regulatory T (TReg). While the appearance of
the IL-10 producing TReg is rapid, within seven days of starting bee venom SCIT, full
tolerance if it is going to occur requires three to five years of treatment (Steinke &
Lawrence, 2014).

Theme 1 - In patients with allergic asthma, can immunotherapy decrease the exacerbations
of asthma symptoms compared to inhaled corticosteroids?
Blumberga, Groes, Haugaard, & Dahl (2006) performed a randomized, double-blind,
placebo-controlled trial with household dust mites (HDM) allergic individuals with asthma to
examine the steroid-sparing effects with the use of SCIT. Those accepted into the trial were
chosen from the outpatient clinic of the Aarhus Kommune hospital, from general practitioners in
the Aarhus area. Criteria for those included into the trial were: 18-60 years of age, allergy to
HDM (Dermatophagoides pteronyssinus, D. pter), shown to have a positive skin prick test
greater than 3 mm and allergen-specific IgE serum, perennial asthma with regular symptoms
requiring long-term treatment with inhaled corticosteroids, and a case history of allergy to HDM
as the cause of the asthma symptoms. Subjects were omitted from the trial if they exhibited: a
positive skin prick test to cat or dog and had daily contact with a pet; positive skin prick test to
the fungus Cladosporium herbarum or Alternaria alternate; previous HDM immunotherapy; use
of inhaled long acting beta agonist during the study; or treatment with beta-blockers. Once
chosen for the trial, patients were randomized into the SCIT to receive injection of D. pter or a
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placebo group that would receive injections containing histamine dihydrochloride. During the
trial there was a baseline period that was followed by three years of immunotherapy treatment.
During the baseline period, inhaled corticosteroid (ICS) were adjusted with a stepwise approach
to define the lowest does needed to maintain asthma control. This was performed by treating all
patients with inhaled fluticasone propionate (FP). The daily dose of ICS was stepwise reduced
every three weeks until their asthma was no longer controlled. Lack of control was determined
when two or more of the following criteria were fulfilled: increase in total symptom scores over
seven days by ≥7 or a daily symptom score by ≥3 over two consecutive days; increase in total
number of salbutamol inhalations over seven days by ≥7; or morning peak expiratory flow ≤90%
of baseline for a minimum of four days of the seven. When the criteria were met, treatment was
continued with dosage one step higher for the trial. During the treatment phase, this stepwise
reduction was repeated after the 1st, 2nd, and 3rd year of therapy. Dose adjustments were not
allowed at any other time during the trial. The immunotherapy process was performed with an
up-dosing performed during an eight-week period with two to three injections received weekly
followed by maintenance treatment for the next three years. Patients were asked to complete
daily diaries during the month of January before starting their immunotherapy and after
treatment for the remaining three years. Asthma symptoms were to be recorded for showing
signs of breathlessness, coughing, wheezing, and chest-tightness. Then asthma symptoms were
further broken down by daytime and nighttime asthma symptoms on a six-point scale (0-5, with
zero indicating no symptoms and five indicating severe symptoms). The use of the medication
(salbutamol) was also recorded in the diaries. Exposure to HDM allergens were evaluated each
January by mattress dust sampling, but no measures were taken to reduce HDM. An analysis of
the difference in treatment between SCIT and the placebo was performed by using the Wilcoxon
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Rank Sum Text on a 5% senescence level. A total of 112 patients were willing and eligible for
screening and 54 of those 112 patients were randomized into the study. After the second year of
treatment, a secondary analysis showed that the modification between the two groups was
statistically significant (p = 0.03), with a median reduction of 50% in the ICS dose for the active
group and 25% in the ICS dose for the placebo group. In addition, after three years of treatment
the median ICS dose reduction was 82% in the active group and 42% in the placebo group (p =
0.17). This corresponds to a median ICS dose of 1000 μg FP daily at baseline to a median ICS
dose of 250 μg FP daily after three years of active SCIT. For the placebo group, the median ICS
dose decreased from 750 μg FP daily at baseline to a median ICS dose of 500 μg FP daily. In
conclusion, it was found that inhaled corticosteroid sparing effects were evident in the patients
with moderate persistent asthma.
This study was limited by its pool of subjects because it only accepted patients from the
outpatient clinic of Aarhus Kommune hospital and from general practitioners in the Aarhus area.
Broadening the search area for potential patients would have provided the study with a more
diverse group and potentially more accurate statistics.
Hui et al. (2014) executed a three-year randomized, double-blind, placebo-controlled trial
studying the effects of SCIT on allergic asthma. The study focused on the allergen of house dust
mites and a sample of children ranging in ages 5-14 years of age with asthma symptoms. The
patients were separated into two groups: the treatment group (n=45; males, 24 and females, 21);
and the control group (n=45; males, 22 and females, 23). With regards to the baseline
parameters there were no statistical differences between the two groups, such as age, gender,
duration of asthma, and dose of inhaled corticosteroids (ICS). Those within the treatment group
received weekly injections of house dust mite serum starting at 20 U/ml with increased
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concentration weekly. The patients in the control group were treated with a desensitization
vaccine. Patients in each group were also treated with ICS according to a pediatric asthma
control trial. The ICS treatment was revised every one to three months throughout the trial.
Once a patient’s symptoms of asthma had been under control for three months the dose of ICS
was decreased. If the patient had been observed as asthma free for six months, then a complete
withdrawal from ICS was issued. Over the three-year period of the study, ICS doses were shown
to gradually decrease within both the treatment group and the control group; however, the
treatment group showed a significantly greater drop in the use of ICS than did the control group.
The discontinuation rate of ICS in the treatment group was (28.9%) as compared to the control
group’s discontinuation rate of (20.0%). Asthma symptoms were recorded during daytime and
nighttime throughout the trial. The asthma symptom scores of the treatment group compared to
those of the control group declined from baseline during the trial just as the ICS dose decreased.
This data demonstrates that asthma symptoms were significantly lower each year of the trial
group as compared to those of the control group (p<0.05), indicating that SCIT is effective and
safe for the treatment of children with allergic asthma to alleviate asthma symptoms and reduce
the doses of ICS that are required.
This study was limited by type of allergen because it only tested the subjects against
household dust mites. Since multiple allergies typically affect people, more tests should be
performed with a larger group of allergens.
Karakoc-Aydiner et al. (2015) performed a three year analysis of the use of SCIT for
children with a longstanding history of allergies who experienced little or no symptomatic relief
by using pharmacotherapy. Forty-eight individuals with mild to moderate persistent asthma
and/or rhinitis were selected for participation according to the Global Initiative for Asthma
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guidelines (GINA) who were sensitive to house mites and who had been seeking treatment at a
facility for a minimum of two years using corticosteroid therapy without improvement. The
qualified patients were given subcutaneous immunotherapy and their symptoms were checked at
baseline, one year, and three years of treatment by using a four-point scale (0 = no symptoms, 1
= mild, 2 = moderate, 3 = severe symptoms). A total medication score was also obtained by
having patients score their use of medications as follows: beta-2 agonists, 1 point;
inhaled/intranasal corticosteroids, 2 points; and 1 corticosteroid tablet, 3 points. During the trial
asthma symptoms significantly improved 3 years after treatment in the SCIT group when
compared with baseline (p = .03). The total asthma symptom score (cough, wheezing,
breathlessness, dyspnea) for those receiving SCIT at baseline was 1.1 (0.8) and by year three was
0.14 (0.26). Showing an 86% improvement in score throughout the trial. The SCIT group
showed a reduction in total medication score at the end of three years when compared to baseline
(p = .01) with the control group. Baseline numbers for SCIT were 2.5 (1.2) and at three years 0.3
(0.7) for an 82% improvement. When looking at the lung function there was not a statistical
difference to show any benefit to the use of SCIT. While using SCIT there was a significant
increase in the number of specific IgG4 levels at both the one year and three year checks as
compared to baseline, but no specific changes in the IgE levels. Karakoc-Aydiner et al. (2015)
continued to discuss the unknown function of IgG4 in the reaction of allergies but speculated that
it was the quality and not the quantity of pollen-specific IgG4 that correlated with the clinical
response after SCIT, suggesting that serum inhibitory antibodies might be useful immunological
markers for monitoring SCIT response. The conclusion at the end of the trial was that by adding
SCIT, patients’ symptoms showed a significant improvement in the four-point scale, and their
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asthma symptoms were in the frequency of daily symptoms and medication use with SCIT as
compare to using only corticosteroids therapy.
This study was limited by its method since it was not a double-blind or a placebocontrolled trial. Because of this, the statistical figures obtained are subject to debate.
Maestrelli, Zanolla, Pozzan, and Fabbri (2004) used a randomized, double-blind,
placebo-controlled trial of 72 individuals ranging in ages 8 to 43 (32.6% < 18 years old)
discussing the possible benefits in the use of immunotherapy to individuals who have an allergen
to house dust mites and suffer from asthma. Each subject was carefully selected based on their
severity of mild to moderate asthma, sensitivity to dust mites upon a skin test, and the presence
of serum-specific IgE (≥ class 3). Patients were rejected from the trial if any of the following
presentations were found during the screening process: respiratory diseases other than asthma;
cardiovascular or immunologic diseases or other severe illnesses; active smoking status; FEV1
persistently less than 70% of predicted value; previous immunotherapy with household dust
mites (HDM) within three years from the start of the study; recurrent asthma exacerbations or
more than two emergency hospitalizations for an asthmatic attack in the previous year; or workrelated symptoms of asthma or occupational asthma. Patients were recruited for the study over a
five-month period and, if accepted into the trial, studied for four years. First, a one-year
observation period was conducted in order to stabilize patients’ symptoms. After the observation
period, an investigator independent from the treatment team randomized each patient to receive
SCIT or a placebo injection for three years. Each patient’s asthma was monitored for sensitivity
during the trial, and drug treatment guidelines were specified according to the recommendations
of GINA. Salbutamol (metered-dose inhaler (MDI), 100 μg) was used as a bronchodilator.
Beclomethasone dipropionate (MDI, 250 μg per actuation) was chosen as the anti-inflammatory
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agent used during the trail. For the duration of the trial no other anti-inflammatory drugs were
allowed, except antihistamine tables for rhinitis. Throughout the trial a clinical assessment was
performed each year in February or March (visit 1), May (visit 2), September or October (visit
3), and December (visit 4). Upon each visit, spirometry measurements were performed and, if
needed, drug treatment was modified depending on the severity and clinical presentation of
asthma. Twenty-three of the initial 95 subjects withdrew from the trial before its conclusion (15
within the placebo group and eight within the active treatment group). At the end of the threeyear trial, the proportion of subjects that did not use bronchodilators was reviewed. For subjects
within the control group, in the observational year 26.4% of patients did not use a
bronchodilator, in year 1 it was 24.2%, in year 2 it was 24.2%, and in year 3 25.3% did not use a
bronchodilator with a difference from the observational year of -1.1%. In contrast, subjects
within the treatment group began the observational year with 22.1% not using a bronchodilator,
year 1 it was 25.3%, year 2 it was 24.1%, and by year 3 the number increased to 28.5% of the
subjects not using a bronchodilator. This results in a difference of +6.4% with a p<.01 which is a
significant reduction in the use of a bronchodilator for the treatment group and suggests a
positive response to immunotherapy treatment for those with allergic asthma.
This study was limited by the low number of participants that were involved. A larger
number of patients would provide more accurate statistics when compared to the population as a
whole.
Mathur and Viswanathan (2014) reviewed studies pertaining to allergic asthma in both
children and adults. One study of 639 adults demonstrated no correlation between the increased
sensitivity of a skin prick test to asthma symptoms, quality of life, emergency room visits,
hospitalizations, lung function or response to treatment. Therefore, while atopy has the potential
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to be present in those with asthma, it is not clear whether atopy is a predictor of the severity of
asthma. In contrast, with children, there is evidence showing that the presence of atopy in early
childhood is a risk factor for the subsequent development of asthma. One of the studies
conducted with 147 children ranging from birth to 10 years of age showed that there was a
relative risk of 17.14 of the subjects having asthma at 10 years of age as well as the presence of
atopy at the same age. The study found that controlling the airway is an important step in
controlling the subjects’ symptoms. Using corticosteroids to lower the eosinophils or
mepolizumab to neutralize monoclonal antibody to IL-5 to reduce eosinophils has shown to
decrease the number of exacerbations in adults with eosinophilic or steroid-dependent asthma.
This analysis was limited because it was not a double-blind or placebo-controlled trial.
Instead, it was a review of other studies that have been performed and this review does not give
any reasonable explanation as to how the numbers were obtained; therefore, they are not as
reliable.
Mener and Lin (2016) performed a comprehensive literature review of articles dated as
recently as 2016 to conclude that immunotherapy can help to reduce the symptoms of asthma for
those suffering with allergies. They analyzed the function of T-helper 1 (Th1) and T-helper 2
(Th2) cells to show how the body reacts to an allergic reaction and why allergen specific
immunotherapy can be effective in a reduction in corticosteroid use as well as inhalers. There
were 34 randomized control trials that were used as the basis for these results. The subjects of
the trials consisted of 920 children ranging in ages from four to 18 with allergic asthma or rhinoconjunctivitis with dust mites being the most highly sensitive allergen. The trials found that in
children with at least mild asthma undergoing three years of SCIT to D. pteronyssinus and D.
farinae, nearly 70% may have a clinically significant response. Another systematic review of 61
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studies with subjects in ages ranging from seven to 71 that evaluated single-allergen
immunotherapy regimens showed high-grade evidence that SCIT improved asthma symptoms.
However, there was low strength of evidence that SCIT improved areas of lung function despite
many the studies showing improvement of bronchial hyper-reactivity compared to those in the
placebo group.
This review was limited because it was a meta-analysis and not a double-blind or
placebo-controlled study. Reviewing many studies does provide valuable information, but a
review does not explain how the underlying statistics were obtained. Because of this, the
numbers are subject to debate.

Theme 2 - Is subcutaneous immunotherapy a more effective treatment plan sublingual
immunotherapy in response to allergic asthma?
Asamoah et al. (2017) performed a meta-analysis on multiple studies searching nine
electronic databases from inception to October 31, 2015. Systematic reviews were
independently screened by two reviewers against pre-defined eligibility criteria and critically
appraised using the Critical Appraisal Skills Programmed quality assessment tool for systematic
reviews. Data was descriptively and thematically synthesized. These studies focused on
deliveries of allergen immunotherapy (AIT) through the following routes: subcutaneous (SCIT;
n = 3); sublingual (SLIT; n = 4); and both SCIT and SLIT (n = 2). The evidence found that
allergen immunotherapy delivered by SCIT and SLIT can improve medication and symptom
scores and measures of bronchial hyperreactivity. Eighty-eight different articles were analyzed
up to 2015 studying the effects of immunotherapy with allergic asthma. The articles mostly
focused on children, but a few articles involved adults as well. The studies assessed the overall
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health, amount of medication usage, quality of life, lung function, and overall safety while
having the SCIT administered. Examples from 10 different studies with 668 people showed that
90% of those tested had improved outcomes for both SCIT and SLIT. Another trial pooled
together information from 21 different studies and found allergen immunotherapy resulted in a
significant reduction in medication compared to the placebo group.
The most promising evidence for SCIT-focused review of asthma symptom reduction
was given by the meta-analysis which included 88 randomized controlled trials of moderate
quality randomizing a total of 3,459 asthma patients. Meta-analysis revealed that 35 trials
demonstrated significant reductions in asthma symptom scores based upon: the estimated
standardized mean difference (SMD) for all allergens combined was −0.59 (95% CI −0.83 to
−0.35) for immunotherapy versus placebo, but there was high diversity between studies
(I2 = 73%). The authors concluded that it would have been necessary to treat three patients
(NNT = 3; 95% CI 3–5) to avoid one patient’s asthma symptoms deteriorating. Patients’ asthma
symptoms showed the most improvement with AIT on: pollen (NNT = 3; 95% CI 2.0–16.0);
animal dander (NNT = 3; 95% CI 2–18); and additional allergens such as molds, chemically
modified allergoids or antigen–antibody complexes (NNT = 3; 95% CI 3–4). A smaller
improvement was observed following HDM’s immunotherapy where six patients would need to
be treated to avoid one deteriorating (NNT = 6; 95% CI 4–16).
Eight studies reported on medication scores, all eight used single allergen
immunotherapy. The studies included 592 patients. Five out of eight of the studies
demonstrated a greater reduction in medication use in the SCIT group as compared to the
comparator arm, and two of the studies did not report the direction of change.
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A systematic review which included nine double-blind placebo-controlled trials found a
statistically significant decrease in allergy symptom scores: SMD −0.95 (95% CI −1.74 to −0.15)
in SLIT administration when compared to the placebo group there was high diversity (I2 = 92%).
Furthermore, seven studies enrolling 220 patients analyzing dust mite allergen presented a
significant (p = 0.02) decrease in rescue medication use: SMD −1.48 (95% CI −2.70 to −0.26)
but significant diverse (I2 = 96%). Subgroup analysis according to age showed a significant
reduction in children (SMD −1.86; 95% CI −3.34 to −0.38) but not in adults (SMD 0.23; 95% CI
−0.33 to 0.78).
Finally, a comparison between SCIT and SLIT was performed in the review, which was
comprised of four trials of asthma patients with the use of HDM immunotherapy. The
information gathered upon completion of the review established a superior reduction in asthma
symptoms in three studies with SCIT compared to SLIT, although one study showed greater
reduction in symptoms with SLIT. All studies were judged to be of moderate quality. Research
of three studies comparing the safety of administration showed that SLIT and SCIT each
reported three local reactions. While SLIT never showed any systemic reactions SCIT reported
four, including one anaphylaxis event (defined as flushing, wheezing and dyspnea requiring
adrenaline) all with positive outcomes. In the end, these studies determined that the overall data
obtained demonstrated substantial evidence based on investigation of the effectiveness and safety
of immunotherapy for the improvement of asthma with the potential to improve medication
usage. There was also evidence to support the theory that the use of SCIT was slightly more
effective in treatment compared to SLIT, but the safety aspect to SLIT was superior to SCIT.
This study was limited because it was not a double-blind or a placebo-controlled trial. It
was a meta-analysis that provided a lot of valuable information, but it did little to give strong

IMMUNOTHERAPY AND ASTHMA

22

statistics and demonstrate how those statistics were obtained in order to stand up against
criticism.
DaVeiga et al. (2017) discussed the risk of SCIT and the possibility of systemic reactions
occurring due to the injections. DaVeiga et al. (2017) stated that over the last 20 years the
possibility of a systemic reaction is around 0.25 to 0.51% per individual injection, and patients
with exquisite sensitivity to individual allergens may be at an elevated risk for a fatal reaction
from SCIT. They continue by stating that it has been theorized that individuals with increased
wheal-flares at the time of allergic testing were more highly allergic and have an increased risk
of a systemic anaphylactic reaction to SCIT. In their study, they followed patients from 2001
through 2007 while 16,375 SCIT injections were administered. During this time there were a
total of 46 systemic reactions that occurred in 20 patients. A rate of a systemic reaction occurred
in 0.28% of patients per injection visit with a mean age of 36 with 65% being female, 90%
white, and 35% with asthma. It was also concluded that 63% of the systemic reactions occurred
in patients with prior systemic reactions, and 83% of reactions occurred within the buildup to
maintenance phase. It was also shown that 50% of the reactions occurred within 30 minutes of
receiving the injection, 39% occurred within 30 to 60 minutes of the injection, and 11% occurred
after 60 minutes of the injection. If a severe reaction did occur, it was within the first 30 minutes
after injection, and 28% of those required the use of an epinephrine pen for treatment. All
patients made a full recovery. After looking at their research of each patient they were able to
conclude that those who had experienced a severe reaction to their allergy skin testing with
larger wheals obtained were six times more likely to experience a systemic reaction compared to
those where were not highly allergic (OR = 5.83; 95% Cl:1.23-27.59, p = 0.026). They also
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determined that the estimated odds of experiencing a systemic reaction increased by 17% for
each additional four plus skin test results.
This study was limited because it was not a double-blind or a placebo-controlled trial and
it lacked sufficient controls. While the authors did conduct their own research, questions
regarding the accuracy of the results could be posed because of the study’s lack of controls.
Khinchi, Poulsen, Carat, Andre’, Hansen, and Malling (2003) performed a randomized,
placebo-controlled, double-blind, double-dummy study comparing sublingual and subcutaneous
immunotherapy in people allergic to birch pollen. They began with 89 patients with a mean age
of 30, having at least two years of seasonal birch pollen rhinoconjunctivitis. The birch pollen
allergy was confirmed by a positive skin-prick test and a positive conjunctival provocation test
using a standardized extract and the presence of specific IgE using the CAP system (a new solidphase immunoassay, fully automated, used for the titration of specific IgE antibodies). Patients
with mild seasonal birch pollen induced asthma were admitted into the trial. Subjects were
excluded based on having perennial allergies, chronic, nonallergic rhinitis or sinusitis, previous
immunotherapy with birch pollen within the past five years, and treatment with beta blockers.
Based on this criteria, 71 patients were assigned into three groups: SLIT-group: which received
sublingual drops and placebo injections; SCIT-group: which received subcutaneous injections
and placebo sublingual drops; and Placebo-group: which received placebo sublingual drops and
placebo subcutaneous injections. The placebo arrangements were conducted with caramelized
sugar for the sublingual and histamine dihydrochloride 0.01, 0.1, and 0.5 mg/ml for injections to
give the same appearance of those receiving the actual birch serums. Treatment during this trial
took place from September 1997 to September 1999, and the sublingual treatments were selfadministered at home while the injections were done in the office. Rhinoconjunctivitis
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symptoms were required to be logged in daily diaries during the birch pollen season (0 = absent,
1 = mild, 2 = moderate, and 3 = severe). Each patient was also administered acrivastine,
levocabastine 0.5 mg/ml eye drops for self-medication. If a patient’s symptoms were
uncontrolled by acrivastine 24 mg, levocabastine 6 eye drops and nasal spray levocabastine 6
puffs, then 5 mg prednisolone tablets were administered. Scoring of the medication was as
follows: 8 mg acrivastine (4 points); 2 eye drops of levocabastine (1 point); 2 puffs of
levocabastine nasal spray (1 point); one tablet prednisolone (6 points). Following each birch
pollen season, the patients were asked to assess their quality of life using the Danish version of
the SF-36 Health Status Questionnaire. Calculations of the immunotherapy-induced treatments
were performed in two different ways. First, by subtracting the pretreatment values for each
patient from the data obtained during the treatment seasons. The first treatment season showed
an improvement of the median rhinoconjunctivitis symptom score by 0.36 score points (on a 0-3
scale) in the SLIT-group (95% Cl 0.18-0.86), by 0.75 score points in the SCIT group (0.02-1.31)
and deterioration by 0.2 score points in the Placebo-group (-1.05-0.22). The median medication
scores showed an increase in scores as well with 0.29 in the SLIT-group (-2.57-0.82), no change
in the SCIT-group (-1.52-2.65) and an increase by 1.35 score points in the Placebo-group (-4.040.12). These numbers infer a statistically significant difference of changes with
rhinoconjunctivitis scores (p < 0.002) and medication scores (p < 0.02) comparing the SLITgroup to the Placebo-group. The SCIT-group was also shown to be statistically significant when
compared to the Placebo-group (p < 0.002 and P <0.002, respectively). However, there was no
statistical difference seen when comparing the SLIT-group and the SCIT-group to each other.
The second method used for calculations evaluated the first treatment season, in 1998, relative to
the pretreatment season. The exposure of pollen during the first treatment season was 2.29 times
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higher when compared to the pretreatment season. As a result, the placebo-treated patients
symptoms scores decreased by a factor of 1.45 (0.87-2.09) and their medication score increased
by a factor of 2.01 (1.02-3.56). The SLIT-group improved in symptoms by a factor 0.78 (0.61.06) and decreased medications score by a factor 1.03 (0.77-1.75) (p < 0.01 and p < 0.05)
resulting in the disease severity being only half of what the Placebo-group was. The SCITgroup’s symptoms increased by a factor 0.48 (0.28-1.02) and reduced medications score by 0.78
(0.3-2.0) showing a disease severity of one-third of the Placebo-group (p < 0.001 and p < 0.02).
As with the first method though, there were no significant differences found between the SLITgroup as compared to the SCIT-group.
This trial was limited because it did not contain a large enough number of participants in
order to provide a good representation of the general population. The trial was performed with a
high quality as compared to others, but a larger number of participants are needed in order to
gain a full understanding of the potential effects of immunotherapy on the general population.
Pokladnikova, Krcmova, and Vlcek (2008) conducted an open-label randomized clinical
trial that was carried out from January 1, 2002 to January 1, 2006, examining the effectives of
SLIT vs SCIT over a three-year period to determine which is more effective not only with
individual symptoms but with costs as well. A total of 64 patients were randomly selected to
take part in three study groups: SLIT, SCIT, and control. Those in the SCIT group were
administered treatment within the clinic, while the SLIT group self-administered at home. All
patients were at least 18 years of age and had a history of seasonal allergic rhinoconjunctivitis
(SARC) for at least two years that was uncontrolled by symptomatic treatment, and moderate
persistent rhinitis (according to the classification of seasonal allergic rhinitis severity based on
Allergic Rhinitis and its Impact on Asthma (ARIA) recommendations, 2001). Each year of the
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trial, patients were asked to evaluate the severity of rhinoconjunctivitis symptoms during the
peak of pollen season before and after immunotherapy treatment. The evaluation was measured
using the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) to obtain its data. The
study compared the proportion of clinically improved patients in the third year of SLIT to the
first year of immunotherapy. For each of the groups reviewed, a clinically significant difference
was observed if the calculated score was at least greater than 0.5 points. After a decrease in the
medication usage related to SARC, it was calculated as mean defined daily dose (DDD) per
anatomical therapeutic class (ATC) using the ATC/DDD methodology. Data was then
categorized among the groups and examined using the X 2 test or Fisher exact test (2-tailed).
Kruskal-Wallis, Wilcoxon tests, analysis of variance, and paired t test were used for variables,
with normal distribution, p < 0.05 considered as statistically significant. Of the 64 people within
the study, 19 received SLIT (SLIT, n = 19), 23 received SCIT (SCIT, n = 23), and 22 were in the
control group (Control, n = 22). Four of the patients who began in the SLIT and control groups
were withdrawn from the trial before the final results were obtained. No statistically significant
differences in characteristics were found between the groups within the baseline. By the end of
the trial the number of clinically improved patients measured by the RQLQ did not significantly
differ between the SLIT and SCIT groups (RQLQ for the SLIT vs SCIT group: 41% vs. 48%, p
≥ 0.75). During each year of the trial there was a clear decrease in the need for symptomatic
medication for the SLIT and SCIT groups, but no significant decrease was indicated for the
control group (SLIT group -56DDD, SCIT group -70DDD; control group 6DDD; p = 0.002).
The study found a significant decrease in symptomatic medication was reached within the first
and second year of immunotherapy treatment, and SCIT patients showed a marginally increased
clinical outcome. As for the cost to the patient, SLIT was received at a slightly lower cost when
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compared to SCIT therapy ($206 vs $299, p = .34). Copayments for the allergen extracts ($84
for SLIT vs. $65 for SCIT; p < .001) and loss of income were the main factors when considering
the overall costs. If the cost of SCIT itself was considered as a fixed cost, then SCIT was
approximately one third less expensive when compared to SLIT (27%, $88 vs. $69; p < .001).
While there was a higher dropout rate in this study, Pokladnikova et al. (2008) does state that
recent studies show noncompliance rates of up to 50% of patients starting SCIT because of the
inconvenience of weekly shots in the clinic and travel time.

In order to evaluate costs, the study considered the following factors: direct medical
costs, including costs of medication and health care services; costs arising from adverse effects
of treatment (medication, emergency department visit, hospitalization); and health care service
costs, including specialist visits (consultations, laboratory tests, diagnostic tests, nurse services),
emergency department visits, and hospitalizations. The health care services costs were
calculated by multiplying the number of units per service and the unit price. The medication
costs were determined from the number of DDDs and the cost per DDD. Travel costs were
computed by multiplying the number of specialist visits and travel costs per specialist visit.

This study was limited because it was not a double-blind or a placebo-controlled trial and
it was based on foreign costs and currency. It also lacked the number of participants needed to
represent the population with good statistical numbers. This study was performed overseas and
although the currency was converted into U.S. dollars for the purposes of the cost analysis, the
costs do not exactly represent the types and amounts of costs that patients located in the United
States would experience when undergoing the same type of treatment.
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Saporta (2012) performed a retrospective, consecutive chart review of allergy patients to
determine the effectiveness of SCIT vs. SLIT. A total of 93 patients were selected that met the
criteria of any age with nasal allergies with or without asthma that has been treated with
immunotherapy for the past six months and has also had two evaluations. The evaluation implies
symptom scoring, evaluation of medication usage, and determination of the peak flow meter
(PFM) value. Evaluations were performed during the trial every three to six months to assess
patients progress. Scoring systems used were based off the scoring of symptoms from none to
severe, presence of asthma, and a recording of allergic activities. Pre-treatments were evaluated
and the amount of medications the patient was taking at the time reflected severity without the
use of immunotherapy treatment. Then the patients were established with a SCIT or SLIT form
of immunotherapy based on consideration of each patient’s distance from trail, age, allergen
severity, and needle phobias with 50 patients receiving SCIT and 43 patients receiving SLIT.
The study was managed so that there were no statistical differences between the two groups,
therefore the patients’ reactivity to allergens in both groups can also be considered the same. As
a result of the trial it was concluded that wheezing and coughing seemed to respond to either
SCIT or SLIT with coughing slightly better with SCIT (p = 0.37) and wheezing better with SLIT
(p = 0.024), and improvement of asthmatic symptoms as well as decreases in short-acting beta
agonist (SABA) use was significant at p < 0.05. The study resulted in findings that validate the
theory that SLIT can be as effective as SCIT to regulate the symptoms of nasal allergies of
patients with or without asthma as well as decrease medication usage. However, considering the
increased risk and difficulty in treating younger children it can be suggested that SLIT should be
considered the main treatment plan for these patients and that SCIT only be used in times of
SLIT failure.
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This study was limited in that it was a retrospective chart review and not double-blind or
a placebo-controlled trial.

Yukselen and Kendirli (2014) performed a meta-analysis from several studies to evaluate
the effectiveness of both SCIT and SLIT in patients with allergic asthma. While analyzing
studies of SCIT, 24 prospective, randomized, studies involving 962 asthmatic patients was
performed and showed a significant improvement in symptoms and drug intake related with
asthma as compared to the placebo group. Concluding immunotherapy was beneficial in 17
(71%) studies, inefficacious in four (17%) studies, and equivocal in three (12%) studies. With
each study being done it was determined that significant steroid-sparing effect of immunotherapy
was shown in moderate persistent asthmatic patients included in those studies. In another study
looking at the effect of SLIT, 452 patients were treated and a marked improvement in symptoms
and a drop-in medication usage was seen regarding asthma. As with SCIT, the steroid sparing
effect of SLIT was observed with the trial. Additional studies were conducted comparing SCIT
and SLIT to determine if there was a difference in the outcome of treatment. The study elected
to treat patients with asthma and rhinitis with SCIT, SLIT, or a placebo for one year to determine
the outcome. The study found that one year of SCIT improved symptom scores of both rhinitis
and asthma while SLIT had benefits only on symptoms of rhinitis. However, medication usage
of both rhinitis and asthma showed a significant decline in both treatment groups. Another group
performing a randomized control trial found similar results stating they observed that the effect
of SLIT on asthma symptoms and drug intake was less eminent than SCIT in the first year;
however, the effect of SLIT was more noticeable in the second year. This group concluded that
both clinical and immunologic improvement begins earlier with SCIT when compared to SLIT in
mite-allergic children with rhinitis and asthma. Yukselen goes on to discuss the safety aspect of
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immunotherapy. He found that SCIT has a risk for both local and systemic adverse reactions;
however, if detected and treated early the symptoms are reversible. It was also found that asthma
could be a risk factor for the systemic reactions of SCIT so those with uncontrolled asthma
should delay SCIT until their symptoms are better controlled. SLIT was investigated specifically
with grass pollen in patients with asthma. Evaluations of side effects potentially related to
asthma, such as cough and wheezing, were observed and no difference was found in the numbers
of such effects between the SLIT and placebo group, and no asthma exacerbations were reported
in relation to SLIT. In conclusion, SCIT and SLIT have both been shown to be effective in
response to allergic asthma. However, SCIT has been slightly more effective with a quicker
response time within the first year of treatment. SLIT could be a reasonable alternative for those
concerned about the potential side effects of immunotherapy, but if choosing SLIT one must do
so with the understanding that it has a slower response time when compared to SCIT.
This analysis was limited because it was a meta-analysis of other studies that have been
performed. Due to this, the methods used to determine the statistics that are presented are not
thoroughly explained and the numbers become open for debate regarding their accuracy.
Yukselen, Kendirli, Yilmaz, Altintas, and Karakoc (2011) performed a randomized,
double-blind, placebo-controlled, double-dummy study over a one-year immunotherapy period.
Focusing the study on SLIT and SCIT in terms of their efficacy in children with rhinitis and
asthma monosensitized by household dust mites (HDM). To have accurate numbers it was
necessary to study each patient’s asthma symptoms and establish a baseline level of medication
scores. To achieve this, patients were asked to participate in follow-up visits for one year before
beginning immunotherapy. Those patients considered for the trial were required to have a
clinical history of at least one year of rhinitis and asthma related to HDM with no history of

IMMUNOTHERAPY AND ASTHMA

31

earlier immunotherapy. Fulfillment of the criteria for asthma was done according to the GINA
guidelines, and the diagnosis of persistent allergic rhinitis was based on criteria in the World
Health Organization consensus statement on allergic rhinitis and its impact on asthma. A
positive skin-prick test, with a wheal of 13 mm or greater was used for HDM, and the presence
of specific immunoglobulin E using the CAP system for both D. pteronyssinus (D.pt.) and D.
farinae (D.f.). During the first year of the trial patients had follow-up visits to assess their
baseline symptom scores so that their medication scores could be adjusted in relation to their
asthma and rhinitis. For patients exhibiting a need, budesonide inhalers (100-800 g/day) and
salbutamol were recommended for controlling their asthma. Rhinitis symptoms were alleviated
with intranasal mometasone and antihistamines. No patient was treated with oral corticosteroids
or leukotriene antagonists. All participants were instructed to take anti-mite measures, for
instance cleaning of bedrooms and carpets and regular washing of teddy bears. In the beginning
of the second year, the immunotherapy period, the patients were randomly placed into three
groups by a computer-generated method, with no significant difference between the three groups
in terms of age (p = 0.51) and gender (p = 0.99). The SCIT group (10 patients) received active
SCIT and placebo sublingual drops, the SLIT group (11 patients) received active SLIT and
placebo subcutaneous injections, and the placebo group (10 patients) received placebo sublingual
drops and subcutaneous injections. SLIT was self-administered at home and drops were taken
each day before meals and held under the tongue for two minutes before swallowing. When
beginning SLIT, one drop of 10 TU/ml was placed and held under the tongue for two minutes
before swallowing. This method was increased by one drop each day for 28 days, then 28 drops
three times per week was considered maintenance. SCIT was also administered in a titration
method with weekly injections starting at 0.2-0.8 ml of 50 TU/ml (weeks 1-3), 0.2-0.8 ml of 500
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TU/ml (weeks 4-8) and 0.2-0.8 ml of 5,000 TU/ml (weeks 9-12). At the end of 12 weeks, the
patient was considered to be on a maintenance dose, which was repeated every fourth week.
Throughout the year patients completed a self-assessment diary each day, scoring the symptoms
of rhinitis (rhinorrhea, sneezing, nasal itching and blocked nose) and asthma (coughing,
wheezing, dyspnea and chest tightness). The rating system used was: 0 = no symptoms, 1 =
mild, 2 = moderate and 3 = severe. Then, a calculation of both the rhinitis and asthma scores
was performed to produce a total symptom score. The scores were calculated as monthly median
values once obtained during the immunotherapy year. The calculations showed a statistically
significant difference in symptoms associated with rhinitis and asthma with both SCIT (p =
0.005 for both) and SLIT (p = 0.008 and p = 0.012) when compared to the baseline year. When
compared to the placebo group, the decrease in symptom scores regarding rhinitis was found to
be significant in the SCIT group (p = 0.03). The SLIT group’s rhinitis symptoms were
significantly reduced when compared to the baseline year (p = 0.008), but when compared to the
placebo group it was not found to be statistically significant. With regards to asthma symptoms,
SCIT showed significantly reduced ailments (p = 0.01), while SLIT exhibited no statistically
significant effect (P = 0.48) when compared to the placebo group. While looking at the
medication usage for both rhinitis and asthma SCIT significantly decreased usage for patients (p
= 0.05 for both) when compared to the placebo group and the baseline year (P = 0.005 and P =
0.02). With SLIT there was a significant decrease in medication scores regarding rhinitis (p =
0.03) and a tendency for a decrease (p = 0.18) in medication for asthma while compared to the
baseline year. But, even with the reduction in medication scores it was not statistically
significant (p = 0.18 for rhinitis and p = 0.16 for asthma). After the total mediation analysis was
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scored, it was determined that the use of both SCIT and SLIT reduced medication usage when
compared to the baseline year (p = 0.005 and p = 0.002).
The limitation of this trial was the brief timeline of one year. Even though a baseline was
obtained before the study began, more than one year is needed to obtain accurate statistical
numbers showing how both SCIT and SLIT react within each patient.

Discussion
With allergic asthma affecting over 300 million people worldwide today (Asamoah et al.,
2017), and the amount of office visits that it brings, there is a significant need for good
evidenced-based studies showing the effects that immunotherapy has for those patients with
uncontrolled asthma. While conducting this review it became clear there are few studies that
have been done comparing SCIT to those taking corticosteroids. A total of six articles were
broken down to compare asthma symptoms with the use of SCIT vs. corticosteroids. Three of
the articles are randomized, placebo-controlled, double-blind trials with good statistical analysis.
The remaining three reviews are meta-analysis added due to lack of additional trials found and
should be reviewed with caution.
Seven articles were reviewed comparing the efficacy of SCIT to SLIT. The use of SLIT
is a newer concept compared to SCIT and there are few studies comparing the two forms of
treatment as well. Two of the articles were performed with randomized, placebo-controlled,
double-blind trials with statistical data, but the number of patients within the study was low. The
other articles were a mix of systemic review, open-label randomized reviews, and chart review
from medical providers but are open for debate without strong statistical values.
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Can immunotherapy decrease the exacerbation of asthma symptoms in patients with
allergic asthma as compared to treatment with inhaled corticosteroids?
An analysis that was provided from 21 studies showed that allergen specific
immunotherapy significantly decreased medication usage with all allergens combined versus a
placebo of -0.53 (95% CI −0.80 to −0.27) with moderate between study heterogeneity
(I2 = 67%). Additional evidence from a study of 50 patients with a moderate risk of bias showed
significant improvement in the patients’ quality of life. Data was also shown that was
inconclusive regarding the impact immunotherapy had on lung function when compared to
placebo. Findings demonstrated that the standardized mean difference for peak expiratory flow
was 0.14% (95% CI -0.33 to 0.61) and forced expiratory volume in one second (FEV1) was 0.32 (95% CI -0.96 to 0.31) (Asamoah et al., 2017). Additional studies were also done
comparing the use of immunotherapy and the use of inhaled corticosteroids on patients suffering
from allergic asthma on a sample size of 90 children ranging in ages 5 to 14 with allergies to
HDM specifically. A treatment therapy of immunotherapy and inhaled corticosteroids as needed
was used for half of the group, while the other half of the group was only given treatments of
inhaled corticosteroids as needed. Over the first year, it was shown that those in the treatment
group significantly reduced the amount of inhaled corticosteroids needed as compared to the
control group. The ICS discontinuation rate in the treatment group (28.9%) was significantly
higher than that in the control group (20.0%) (Z=−2.327, p=0.020) (Hui et al., 2014).
Considering the large population that allergies and allergic asthma affect, few studies
have been done to understand it. Double-blinded trials by Blumberga, Groes, Haugaard, & Dahl
(2006); as well as Maestrelli, Zanolla, Pozzan, & Fabbri (2004); and Hui et al. (2014) showed the
most valuable statistics in concerns of subcutaneous immunotherapy and its effectiveness to
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decrease the use of medications. Other studies by Karakoc-Aydiner et al. (2015) and Mathur &
Lin (2016) also show benefits with immunotherapy but are less specific in how their studies were
performed. Using smaller sample sizes and without the use of double-blind studies makes for a
debate on the accuracy of the numbers. Now, more randomized, double-blind, placebocontrolled studies need to be conducted with larger sample sizes. The better the studies the more
confident we can be in telling patients just how effective immunotherapy can be when compared
to inhaled corticosteroids and other antihistamines used to fight off allergies and allergic asthma.

In patients with allergic asthma, is subcutaneous immunotherapy (SCIT) or sublingual
immunotherapy (SLIT) a more effective treatment plan in managing to allergic asthma?

Regardless of the form of treatment, the safety of the patient is always a concern when
patients are given anything to help alleviate their symptoms. When injecting a patient with an
allergen that is known to cause a reaction there is a concern of a systemic anaphylactic reaction
that could compromise airflow, as well as the fact that not all patients want to put themselves
through a weekly injection. While no single case of mortality has ever been reported with SLIT,
this is not the case with SCIT (Saporta, 2012). This is just one reason why an individual might
not want to start on subcutaneous immunotherapy. The alternative to a subcutaneous injection
could be SLIT, but just how much safer or effective is SLIT compared to a subcutaneous
injection? Studies have shown that with SLIT asthma medication usage can decrease over a
years’ time, but only SCIT was able to improve the symptoms of both rhinitis and asthma while
SLIT had benefits only on the symptoms of rhinitis (Yukselen & Kendirli, 2014). Each of SLIT
and SCIT will regulate the number of T cells that are involved with an allergic response by
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suppressing Th1 and Th2 causing a reduction to the responses of a specific allergen. In trials,
SCIT was shown to have a much quicker response than SLIT within the first year, and it was
shown that some lower dosed treatments of SLIT might not become effective until the second
year of treatment (Nelson, 2014). However, while SCIT has been shown to be more effective in
the symptomatic benefits seen there are additional risks when compared to SLIT. SCIT has been
shown to have the risks of both a local and a systemic adverse reaction, such as an anaphylactic
response, but if caught early these reactions can be reversed with proper treatment to reverse the
effects. SLIT is only known to have local side effects of mild itching or swelling associated with
it, and no anaphylactic reactions have been linked to it. Therefore, SLIT could be considered as
an initial course of treatment, instead of SCIT, when dealing with aspects in practice such as a
younger child, phobias of needles, or long drives to the clinic.

The use of SLIT is a newer concept compared to SCIT and studies are just now really
starting to come out comparing the two therapies. Khinchi, Poulsen, Carat, Andre’, Hansen, and
Malling, as well as Yukselen, Kendirli, Yilmaz, Altintas, and Karakoc all performed trials
comparing the differences between SCIT and SLIT. Both used randomized, double-blind,
placebo-controlled groups so as to obtain more accurate unbiased statistical numbers. Other
studies that were found include meta-analysis papers that discussed and compared findings with
other trials conducted. The studies were not as detailed in their findings and while statistics were
given, they are not as supported medically as the randomized, double-blind trials. Data found
did show a slightly more beneficial usage with SCIT, but SLIT was shown to be a comparable
substitute if needed. As discussed above, the safety of SCIT and SLIT must be considered when
choosing a form of treatment. It is important for medical providers to have knowledge in order
to give patients a full understanding of the treatment options that are being presented and the
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potential side effects of SCIT and SLIT. Therefore, more research needs to be done comparing
both SCIT and SLIT with larger sample sizes and randomized, controlled groups involved in
order to provide more accurate and reliable information for medical providers and patients.

In conclusion, the literature supports the statement that immunotherapy can help patients
with allergies and allergic asthma to reduce the amount of inhaled corticosteroids that are needed
to lessen the severity of their symptoms that lead to acute exacerbations and require hospital
visits. Although there were not a great number of quality studies found, there was enough
literature supporting positive findings associated with SCIT and SLIT to warrant further research
and studies. Based on the studies reviewed, SCIT has been shown to be a slightly more effective
treatment than SLIT. However, SLIT can be utilized as an alternative to SCIT. More research is
needed on these topics with larger sample sizes in order to fully understand the pathophysiology
behind immunotherapy. This additional research is necessary in order to help medical providers
better educate themselves and their patients about the benefits associated with immunotherapy,
and to better determine the effectiveness of both SCIT and SLIT.

Application to Clinical Practice
It is almost inevitable that those who work as a primary care provider will treat numerous
patients with allergies. Allergies is a world-wide condition that causes a cough, nasal
congestion, runny nose, itchy eyes, and even sleeping difficulties. If these symptoms are not
controlled at an early age there is chance of acquiring allergic asthma as well.
During the first stage of allergies over-the-counter medications such as Loratadine,
cetirizine hydrochloride, Fexofenadine, and diphenhydramine are commonly used
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antihistamines. For some patients, this is enough to keep their allergies under control and not
interfere with their active daily living, but for others the symptoms can progress causing
reactions that can potentially react with one’s lungs leading to asthma conditions. If this occurs,
then a combination treatment of antihistamines with inhaled corticosteroids is needed to keep the
symptoms under control. If the condition continues to progress, and the symptoms persist on a
daily basis, then immunotherapy should be considered by the provider and the patient should be
referred for allergy testing.

If a patient has been on a long-acting beta agonist and corticosteroids and their asthma is
still not under control, a medical provider should discuss immunotherapy with them. The
medical provider should explain the process of immunotherapy and how treatment can gradually
reduce a patient’s immune-system response to certain allergy triggers. While testing for
allergen-specific immunoglobulins is not normally performed within a primary care facility, the
weekly injections that are administered can be provided by the patient’s primary care provider if
this arrangement is more convenient for the patient. By the end of the treatment, the patient’s
immune system builds up a tolerance to the allergens over time and the patient’s allergic
reactions diminish. In turn, the patient’s asthma symptoms should decrease as well.

Throughout the course of receiving immunotherapy it is important to educate the patient
regarding what triggers their symptoms and ways that they can avoid encountering them.
Certain medications might be needed in the beginning until the patient’s immune system can
adjust to what is happening within the body. But, over time, daily usage should decrease
resulting in fewer exacerbations and better active daily living.
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